24.74

1.14% 0.28

Adaptive Biotechnologies Corp (ADPT)

Overview News Price History Option Chain Financials Why ADPT Down? Discussions Forecast

Adaptive Biotechnologies Corp stock is traded at $24.74, with a volume of 1.74M. It is up +1.14% in the last 24 hours and up +15.45% over the past month. Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Previous Close:

$24.46

Open:

$24.27

24h Volume:

1.74M

Relative Volume:

0.61

Market Cap:

$3.94B

Revenue:

$295.41M

Net Income/Loss:

$-49.64M

P/E Ratio:

-75.57

EPS:

-0.3274

Net Cash Flow:

$-29.54M

1W Performance:

-0.76%

1M Performance:

+15.45%

6M Performance:

+54.24%

1Y Performance:

+91.49%

1-Day Range:

$24.00

$24.95

1-Week Range:

$24.00

$26.16

52-Week Range:

$11.92

$26.16

Adaptive Biotechnologies Corp Stock (ADPT) Company Profile

Name

Adaptive Biotechnologies Corp

Sector

Healthcare (1080)

Industry

Diagnostics & Research (50)

Phone

206-659-0067

Address

1165 EASTLAKE AVE E, SEATTLE, WA

Employee

624

Twitter

@adaptivebiotech

Next Earnings Date

2026-07-29

Latest SEC Filings

ADPT's Discussions on Twitter

Compare ADPT vs TMO, DHR, NTRA, IDXX, A

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADPT Adaptive Biotechnologies Corp	24.74	4.02B	295.41M	-49.64M	-29.54M	-0.3274
TMO Thermo Fisher Scientific Inc	588.29	222.96B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	202.45	144.67B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	309.93	45.54B	2.50B	-226.32M	71.51M	-1.6412
IDXX Idexx Laboratories Inc	550.96	44.95B	4.45B	1.10B	1.06B	13.59
A Agilent Technologies Inc	148.53	41.87B	7.23B	1.41B	1.09B	4.979

Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-02-25	Resumed	Morgan Stanley	Equal-Weight
Sep-30-25	Initiated	Guggenheim	Buy
Jun-18-25	Initiated	Craig Hallum	Buy
Mar-21-25	Upgrade	Goldman	Neutral → Buy
Jul-05-23	Resumed	JP Morgan	Overweight
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Dec-21-22	Upgrade	Piper Sandler	Neutral → Overweight
Aug-25-22	Initiated	Credit Suisse	Underperform
Jun-03-22	Initiated	Piper Sandler	Neutral
Feb-16-22	Reiterated	BTIG Research	Buy
Feb-16-22	Reiterated	BofA Securities	Buy
Feb-16-22	Reiterated	Goldman	Neutral
Feb-16-22	Reiterated	JP Morgan	Overweight
Oct-15-21	Resumed	Cowen	Outperform
Mar-03-21	Downgrade	Goldman	Buy → Neutral
Oct-08-20	Resumed	BTIG Research	Buy
Sep-09-20	Initiated	Morgan Stanley	Equal-Weight
Jun-03-20	Initiated	Goldman	Buy
Jul-23-19	Initiated	BTIG Research	Buy
Jul-22-19	Initiated	BofA/Merrill	Buy
Jul-22-19	Initiated	Cowen	Outperform
Jul-22-19	Initiated	Goldman	Neutral
Jul-22-19	Initiated	Guggenheim	Buy
Jul-22-19	Initiated	William Blair	Outperform

View All

Adaptive Biotechnologies Corp Stock (ADPT) Latest News

Aug 14, 2026

Dimensional Fund Advisors LP Cuts Stock Holdings in Adaptive Biotechnologies Corporation $ADPT - MarketBeat

Aug 14, 2026

Aug 13, 2026

576,266 Shares in Adaptive Biotechnologies Corporation $ADPT Bought by Wasatch Advisors LP - MarketBeat

Aug 13, 2026

Adaptive Biotechnologies (ADPT) Stock Looks Fair On Cash Flow Yet Rich On Sales - simplywall.st

Aug 13, 2026

Aug 12, 2026

Adaptive Biotechnologies CCO Susan Bobulsky sells $75,000 in shares By Investing.com - Investing.com Australia

Aug 12, 2026

Adaptive Biotechnologies CCO Susan Bobulsky sells $75,000 in shares - Investing.com

Aug 12, 2026

Adaptive Biotechnologies (NASDAQ:ADPT) Insider Susan Bobulsky Sells 3,000 Shares of Stock - MarketBeat

Aug 12, 2026

Adaptive Biotechnologies (ADPT) CCO Bobulsky sells 3,000 shares under plan - Stock Titan

Aug 12, 2026

Aug 11, 2026